InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports Q2 2025 Results and Advances Late-Stage Neuropsychiatry Programs
November 13, 2025
This article has been disseminated on behalf of Cybin Inc. and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN) reported second-quarter 2025 results and recent business highlights, noting strong institutional demand for its completed financing, which Interim CEO Eric So said reinforces confidence in the company’s science, differentiated therapeutic candidates and ability […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Present at Jefferies Global Healthcare Conference in London
November 12, 2025
This article has been disseminated on behalf of Cybin Inc. and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical-stage neuropsychiatry company developing proprietary drug discovery platforms and delivery systems to transform mental healthcare, today announced that George Tziras, chief business officer, will present at the Jefferies Global Healthcare […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Sets Nov. 13 Call to Review Q2 Results and Business Update
November 6, 2025
This article has been disseminated on behalf of Cybin Inc. and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN), will host a conference call and webcast at 8 a.m. ET Thursday, Nov. 13, 2025, to provide a business update and report financial results for its second quarter ended Sept. 30, 2025. To […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Participate in Guggenheim 2nd Annual Healthcare Innovation Conference
November 5, 2025
This article has been disseminated on behalf of Cybin Inc. and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical stage neuropsychiatry company focused on transforming mental healthcare through proprietary drug discovery and delivery technologies, announced that Chief Business Officer George Tziras will participate in a fireside chat at […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Chief Medical Officer to Speak at 2025 Milken Institute Future of Health Summit
November 3, 2025
This article has been disseminated on behalf of Cybin Inc. and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical-stage neuropsychiatry company pioneering transformative mental health treatments, today announced that its Chief Medical Officer, Amir Inamdar, will participate in a panel discussion at the 2025 Milken Institute Future of […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Closes US$175 Million Registered Direct Offering Led by Top Healthcare Investors
October 31, 2025
This article has been disseminated on behalf of Cybin Inc. and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical-stage neuropsychiatry company pioneering next-generation mental health therapeutics, announced the closing of its previously disclosed registered direct offering for gross proceeds of approximately US$175 million. The financing included 22,277,750 common […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces US$175M Registered Direct Offering With Warrants Priced at US$6.51
October 28, 2025
This article has been disseminated on behalf of Cybin and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN) announced a registered direct offering of 22,277,750 common shares and, in lieu of shares for certain investors, pre-funded common share purchase warrants at US$6.51 per share or pre-funded warrant for aggregate gross proceeds of US$175,009,911.45; […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Highlights Clinical and Regulatory Milestones, Prepares for Upcoming Catalysts
September 24, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage breakthrough neuropsychiatry company, outlined key advancements across its proprietary drug discovery platforms and upcoming milestones. The Company emphasized its intellectual property portfolio extending through 2041 and its scalable manufacturing partnership with Thermo Fisher Scientific for the CYB003 program. Key near- and mid-term catalysts include topline data […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Executives to Present at TD Cowen Neuropsychiatry & Epilepsy Summit
September 11, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation treatment options, announced that Chief Medical Officer Amir Inamdar and Chief Business Officer George Tziras will participate in a fireside chat at TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on Sept. 17, 2025, at 9:20 a.m. ET. To […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Completes Enrollment in Phase 2 CYB004 Study for Generalized Anxiety Disorder
September 8, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation treatment options, announced it has completed enrollment in its Phase 2 study of CYB004, a proprietary deuterated dimethyltryptamine (DMT) program for the treatment of Generalized Anxiety Disorder (GAD). Topline data are expected in the first quarter of 2026. Interim CEO Eric So […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Present at H.C. Wainwright Global Investment Conference
September 4, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation treatment options, announced that Chief Business Officer George Tziras will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on Sept. 8, 2025, at 11:00 a.m. ET. To view the full press release, visit https://ibn.fm/jkHN9 About Cybin […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Participate in Cantor Global Healthcare Conference
September 3, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation treatment options for mental healthcare, announced that Chief Medical Officer Amir Inamdar will take part in a fireside chat at the Cantor Global Healthcare Conference, scheduled for Sept. 3–5, 2025. The session will be webcast live on Friday, Sept. 5, at 10:20 […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Appoints Co-Founder Eric So as Interim CEO
September 2, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) announced that, effective Sept. 2, 2025, Doug Drysdale stepped down as Chief Executive Officer and was succeeded on an interim basis by Co-Founder and President Eric So. The Board of Directors has formed a committee to conduct a search for a new CEO to lead the Company through […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives Australian Approval to Begin EMBRACE Phase 3 Study of CYB003
August 26, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company focused on next-generation treatment options, announced approval in Australia to conduct the EMBRACE study, the second pivotal trial in PARADIGM, its Phase 3 multinational program evaluating CYB003, a proprietary deuterated psilocin analog. Approval was granted through the Clinical Trial Notification scheme, with clearance from […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports Annual Meeting Voting Results
August 19, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation mental healthcare treatments, announced the results of its annual meeting of shareholders held Aug. 18, 2025. A total of 90 shareholders were represented in person or by proxy, holding 11,264,212 common shares, which accounted for 48.92% of the Company’s issued and outstanding […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports Q1 2025 Results, Advances Phase 3 Depression Program and Nears Completion of Phase 2 Anxiety Study
August 14, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation mental health treatments, reported unaudited Q1 2025 results and key program updates. The company gained European Clinical Trial Application and UK MHRA approval to begin EMBRACE, expanding its multinational Phase 3 PARADIGM program of CYB003 for adjunctive treatment of major depressive disorder […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives EU Approval to Launch EMBRACE Phase 3 MDD Study
August 7, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company, announced European approval to initiate its EMBRACE(TM) Phase 3 study in Ireland, Poland, and Greece. EMBRACE is part of the Company’s PARADIGM(R) program evaluating CYB003, a proprietary deuterated psilocin analog granted Breakthrough Therapy Designation by the FDA for Major Depressive Disorder. The study will […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Present at Canaccord Genuity Growth Conference
August 6, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation mental health treatments, announced that CEO Doug Drysdale will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston. The live webcast will take place at 2:30 p.m. ET, with an archived version […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Receives MHRA Approval to Launch Second Phase 3 Trial for CYB003 in Depression
July 17, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company, announced UK MHRA approval to initiate EMBRACE, the second pivotal trial in its Phase 3 PARADIGM program evaluating CYB003, a proprietary deuterated psilocin analog for Major Depressive Disorder (MDD). CYB003 previously received Breakthrough Therapy Designation from the U.S. FDA. EMBRACE will enroll 330 patients with […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures $50 Million in Convertible Debenture Financing from High Trail
July 2, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company developing next-generation psychedelic-based treatments, has closed a private placement with High Trail Special Situations LLC for $50 million in unsecured convertible debentures, as part of an agreement that allows for up to $500 million in total funding. The financing will support the advancement of Cybin’s […]
InvestorNewsBreaks – Psyence Biomedical Ltd. (NASDAQ: PBM) to Present at Psychedelic Science 2025
June 18, 2025
Psyence Biomed (NASDAQ: PBM) has announced that its Chief of Global Impact, Mary-Elizabeth Gifford, was selected as a featured speaker at Psychedelic Science 2025 (“PS2025”) – the world’s largest international gathering focused on psychedelic research, biopharma, medicine, policy, and culture. Hosted by the Multidisciplinary Association for Psychedelic Studies (“MAPS”), the highly anticipated conference is taking […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights Progress on Phase 3 Psychedelic Therapeutics Program
June 13, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) issued a corporate update emphasizing continued momentum in its clinical pipeline, including the advancement of its lead candidate CYB003 into Phase 3 development. CEO Doug Drysdale underscored the growing regulatory clarity around psychedelic therapeutics and expressed optimism that Cybin’s IP portfolio and clinical strategy position the company to help […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak at H.C. Wainwright Neuro Perspectives Conference
June 12, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that Chief Executive Officer Doug Drysdale will participate in a virtual fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Conference, scheduled for June 16–17, 2025. The company is advancing next-generation neuropsychiatric treatments aimed at transforming mental healthcare. To view the full press release, visit https://ibn.fm/BjhYH About […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak on Pivotal Trials Panel at Psychedelic Science 2025
June 11, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will speak at the Psychedelic Science 2025 Conference, held June 16–20 in Denver. Drysdale will participate in the panel “The Home Stretch: Pivotal Trials and Preparing for Launch” on Thursday, June 19 at 9:30 a.m. MDT. He emphasized the importance of collaborative dialogue in […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB004 Anxiety Treatment Candidate
June 3, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company focused on next-generation mental health therapies, announced the issuance of U.S. patent 12,318,477 supporting its CYB004 program, a deuterated DMT candidate being developed for generalized anxiety disorder (“GAD”). The patent, which covers novel intramuscular formulations of DMT and related compounds, extends exclusivity through 2040. CEO […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Discuss Phase 3 Progress and Industry Trends in May 29 Fireside Chat
May 22, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will join a Water Tower Research Fireside Chat on May 29, 2025, at 11 a.m. ET. The discussion will cover Cybin’s CYB003 Phase 3 program, recent clinical partnerships, its collaboration with Thermo Fisher, and insights on the evolving regulatory landscape for psychedelics. The event […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Applauds FDA Support for Psychedelic Therapeutics, Advances Phase 3 Trials
May 20, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) welcomed recent comments from FDA Commissioner Dr. Martin Makary endorsing the accelerated development of psychedelic therapeutics. The company, which is conducting Phase 3 trials of CYB003 for major depressive disorder (MDD) and Phase 2 trials of CYB004 for generalized anxiety disorder (GAD), said the FDA’s openness validates its mission […]
Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform
May 19, 2025
Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among veterans—a movement recently spotlighted by The Wall Street Journal. After undergoing ibogaine and DMT therapy in Mexico in 2018, Luttrell described the experience as […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Taps Thermo Fisher for Phase 3 and Commercial Production of CYB003
May 15, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) has partnered with Thermo Fisher Scientific to support Phase 3 clinical supply and potential commercial manufacturing of CYB003, its proprietary deuterated psilocin treatment for major depressive disorder (MDD). The agreement expands on Cybin’s existing U.S.-based manufacturing operations, with Thermo Fisher handling drug substance in South Carolina and capsule production […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Alliance Global Partners Healthcare Showcase on May 21
May 14, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase on May 21, 2025. The session will be webcast live at 1:40 p.m. ET and later available via the company’s investor relations site. To view the full press release, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB003 Depression Treatment
May 8, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company, announced the issuance of U.S. patent 12,291,499 for its CYB003 program targeting major depressive disorder (MDD). The patent covers pharmaceutical compositions and oral dosage forms related to Cybin’s proprietary deuterated psilocin analog and offers exclusivity through 2041. The company is currently dosing patients in a Phase […]
NECANN Cannadelic Miami 2025 to Ignite Miami’s Wellness Evolution
May 6, 2025
Researchers, scholars, wellness seekers, and industry experts are invited to attend the NECANN Cannadelic Miami 2025, held at the Miami Airport Convention Center, Miami, FL, from May 23 to 24, 2025. This transformative two-day event empowers attendees to explore the frontiers of emerging therapies, plant-based medicine, and next-gen healing. Based on the inspiring theme “Elevate […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak at Milken Global Conference on Medical Breakthroughs
May 1, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will speak at the 28th Annual Milken Institute Global Conference on May 5 at 2:30 p.m. PDT. He will join the panel “The Global Landscape and Opportunities for Medical Breakthroughs” to discuss innovation in drug development and next-generation mental health treatments. The event will […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Phase 3 Trial Network to 18 Sites for CYB003 in Depression
April 23, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced the expansion of its strategic partnership agreements to include 18 U.S. clinical sites for its multinational Phase 3 trial of CYB003, a next-generation psychedelic-based therapy for major depressive disorder (MDD). The APPROACH study, part of Cybin’s PARADIGM program, is expected to grow to approximately 45 sites. By leveraging […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Forms Strategic Partnership With Osmind to Prepare for Mental Health Drug Commercialization
April 21, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company, has entered a strategic partnership with Osmind, a technology and services provider with a network of over 800 U.S. psychiatry clinics. The collaboration aims to lay the groundwork for the commercialization of Cybin’s clinical programs CYB003, in Phase 3 for major depressive disorder, and CYB004, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports Q3 Financials, Advances Clinical Programs
February 11, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced third-quarter financial results and recent developments in its neuropsychiatry pipeline. The company continues advancing its lead programs, including CYB003, which has entered a multinational Phase 3 trial for major depressive disorder, and CYB004, now in Phase 2 testing for generalized anxiety disorder. Financially, Cybin reported a net loss of […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Launches Strategic Partnership Program with Segal Trials for Phase 3 MDD Study
January 15, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a neuropsychiatry platform company, announced its first strategic partnership agreement (“SPA”) with Segal Trials as part of its multinational pivotal Phase 3 program for CYB003, targeting Major Depressive Disorder (“MDD”). Segal Trials, a South Florida-based research network specializing in psychiatry and psychedelics, joins Cybin in advancing its Phase 3 […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights 2024 Achievements and Outlines Key 2025 Milestones
January 13, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company, summarized its 2024 accomplishments and detailed upcoming 2025 milestones. CEO Doug Drysdale highlighted advancements in its pipeline of tryptamine serotonin receptor agonists, including CYB003, a deuterated psilocin program for major depressive disorder (“MDD”), and CYB004, a deuterated dimethyltryptamine in intramuscular form for generalized anxiety disorder […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Lytham Partners Healthcare Summit
January 10, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company, announced that CEO Doug Drysdale will join a fireside chat at the virtual Lytham Partners 2025 Investor Healthcare Summit on Jan. 13. The live webcast begins at 11:30 a.m. ET, with an archived version accessible afterward on the company’s investor relations site. To view the […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights Promising Advances in Depression and Anxiety Treatment at ACNP Annual Meeting
December 10, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) presented compelling data from its clinical programs at the American College of Neuropsychopharmacology (“ACNP”) Annual Meeting, including 12-month efficacy results from its Phase 2 study of CYB003, a deuterated psilocin program for Major Depressive Disorder (“MDD”), which demonstrated a 100% response rate and 71% remission rate after two doses. […]